+

WO2007012670A3 - Composes derives de 5-benzylidene imidazolidine 2,4-dione et leur utilisation en tant qu'antagonistes de mchr-1 - Google Patents

Composes derives de 5-benzylidene imidazolidine 2,4-dione et leur utilisation en tant qu'antagonistes de mchr-1 Download PDF

Info

Publication number
WO2007012670A3
WO2007012670A3 PCT/EP2006/064793 EP2006064793W WO2007012670A3 WO 2007012670 A3 WO2007012670 A3 WO 2007012670A3 EP 2006064793 W EP2006064793 W EP 2006064793W WO 2007012670 A3 WO2007012670 A3 WO 2007012670A3
Authority
WO
WIPO (PCT)
Prior art keywords
medicine
mchr
imidazolidine
benzylidene
dione
Prior art date
Application number
PCT/EP2006/064793
Other languages
English (en)
Other versions
WO2007012670A2 (fr
Inventor
Fabrice Balavoine
Eric Nicolai
Eric Sartori
Original Assignee
Cerep
Fabrice Balavoine
Eric Nicolai
Eric Sartori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerep, Fabrice Balavoine, Eric Nicolai, Eric Sartori filed Critical Cerep
Publication of WO2007012670A2 publication Critical patent/WO2007012670A2/fr
Publication of WO2007012670A3 publication Critical patent/WO2007012670A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne les composés de formule générale (I) suivante :dans laquelle : Ar1, L1, R1, R2, R3, R4 R5, R6, L2, Q, et n sont tels que définis dans les revendications, ainsi que leur procédé de préparation. L'invention concerne également l'utilisation des composés de formule (I)en tant que médicament, et plus particulièrement pour la préparation d'un médicament destiné au traitement de l'obésité et des maladies associées, d'un médicament coupe-faim et/ou d'un médicament entraînant une perte de poids, d'un médicament destiné au traitement de la dépression et/ou de l'anxiété, et plus généralement d'un médicament destiné au traitement d'une maladie associée aux récepteurs MCH (mélanine concentrating hormone).
PCT/EP2006/064793 2005-07-28 2006-07-28 Composes derives de 5-benzylidene imidazolidine 2,4-dione et leur utilisation en tant qu'antagonistes de mchr-1 WO2007012670A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0508074A FR2889191A1 (fr) 2005-07-28 2005-07-28 Composes derives de 5-benzylidene imidazolidine 2,4-dione et leur utilisation en tant qu'antagonistes de mchr-1
FR0508074 2005-07-28

Publications (2)

Publication Number Publication Date
WO2007012670A2 WO2007012670A2 (fr) 2007-02-01
WO2007012670A3 true WO2007012670A3 (fr) 2007-04-12

Family

ID=36169065

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/064793 WO2007012670A2 (fr) 2005-07-28 2006-07-28 Composes derives de 5-benzylidene imidazolidine 2,4-dione et leur utilisation en tant qu'antagonistes de mchr-1

Country Status (2)

Country Link
FR (1) FR2889191A1 (fr)
WO (1) WO2007012670A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7535657B2 (ja) 2020-08-28 2024-08-16 セルロス バイオテック 新規チオヒダントイン誘導体及びその用途

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102432544B (zh) * 2011-11-17 2014-05-21 天津医科大学 5-取代苄亚甲基咪唑烷-2,4-二酮类衍生物及其应用
CA3121202A1 (fr) 2018-11-30 2020-06-04 Nuvation Bio Inc. Composes pyrrole et pyrazole et leurs procedes d'utilisation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050119312A1 (en) * 2002-07-09 2005-06-02 Cheng Peter T. Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050119312A1 (en) * 2002-07-09 2005-06-02 Cheng Peter T. Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
"AKos Screening Library", 26 September 2003, AKOS CONSULTING AND SOLUTIONS GMBH, BASEL, CH-4010, SWITZERLAND *
"Ambinter Stock Screening Collection", 29 January 2004, AMBINTER, 75016 PARIS, FRANCE *
"Chembridge Screening Library", 13 June 2004, CHEMBRIDGE CORPORATION, SAN DIEGO, CA, 92127 USA *
"ChemDiv, Inc. Product Library", 20 May 2004, CHEMDIV, INC. SAN DIEGO, CA, 92121 USA *
"TimTec Overseas Stock", 7 August 2004, TIMTEC, INC. NEWARK, DE, 19711 USA *
"Vitas-M Screening Collection", 8 October 2004, VITAS-M, MOSCOW, 119829, RUSSIA *
BENASSI, R. ET AL.: "NMR spectroscopic and theoretical structural study of 5-exo-methylene-substituted hydantoins", JOURNAL OF MOLECULAR STRUCTURE, vol. 441, 1998, pages 47 - 62, XP002409757, ISSN: 0022-2860 *
CEGAN, ALEXANDR: "Hydrolysis kinetics and mechanism of 5-arylidene-3-arylimidazolidine-2,4-dione", SBORNIK VEDECKYCH PRACI - VYSOKA SKOLA CHEMICKOTECHNOLOGICKA PARDUBICE, vol. 52, 1988, pages 41 - 53, XP001247997, ISSN: 0553-2124 *
DATABASE CHEMCATS Chemical Abstracts Service, Columbus, Ohio, USA; 13 June 2004 (2004-06-13), XP002409767 *
DATABASE CHEMCATS Chemical Abstracts Service, Columbus, Ohio, USA; 20 May 2004 (2004-05-20), XP002409764 *
DATABASE CHEMCATS Chemical Abstracts Service, Columbus, Ohio, USA; 26 September 2003 (2003-09-26), XP002409768 *
DATABASE CHEMCATS Chemical Abstracts Service, Columbus, Ohio, USA; 29 January 2004 (2004-01-29), XP002409766 *
DATABASE CHEMCATS Chemical Abstracts Service, Columbus, Ohio, USA; 7 August 2004 (2004-08-07), XP002409765 *
DATABASE CHEMCATS Chemical Abstracts Service, Columbus, Ohio, USA; 8 October 2004 (2004-10-08), XP002409769 *
KHODAIR A I: "Glycosylation of 2-thiohydantoin derivatives. Synthesis of some novel S-alkylated and S-glucosylated hydantoins", CARBOHYDRATE RESEARCH, ELSEVIER SCIENTIFIC PUBLISHING COMPANY. AMSTERDAM, NL, vol. 331, no. 4, 23 April 2001 (2001-04-23), pages 445 - 453, XP004235522, ISSN: 0008-6215 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7535657B2 (ja) 2020-08-28 2024-08-16 セルロス バイオテック 新規チオヒダントイン誘導体及びその用途

Also Published As

Publication number Publication date
WO2007012670A2 (fr) 2007-02-01
FR2889191A1 (fr) 2007-02-02

Similar Documents

Publication Publication Date Title
WO2007012661A8 (fr) Composes derives d'hydantoïne et leur utilisation en tant qu'antagonistes de mchr-1
Parkman et al. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis
MA29088B1 (fr) Composes d'indazole-carboxamide.
CL2004000827A1 (es) Compuestos derivados de 1,2-diazoles o 1,3-diazoles condensados con un heterociclo, composicion farmaceutica; y uso para tratar enfermedades moduladas por antagonistas de receptores canabinoides, tales como obesidad y sobrepeso.
EP2298734A3 (fr) Derivés de cyclobutyl amine
WO2007062999A3 (fr) Derives de indole-2-yl amide substitues en 1,5
PT1235787E (pt) Receptores agonistas beta2 adrenergicos
MX2008000255A (es) Activadores de urea glucocinasa.
UA93910C2 (ru) Алкоксиалкилзамещенные циклические кетоэнолы и средство для борьбы c вредителями
WO2005079756A3 (fr) Methodes et compositions de traitement de troubles psychiatriques
EP1398029A8 (fr) Derivés de pyrazole,substitués en position 3 ayant une affinité envers le NR3B1 récepteur
WO2010011836A3 (fr) Traitement de divers troubles avec de la dihydroxy-7,8 flavone et ses dérivés
EP1740559A4 (fr) Derives de phenyle 1,3,5-substitues utiles comme inhibiteurs de la beta-secretase pour le traitement de la maladie d'alzheimer
MX2010006230A (es) Derivados de arilamida substituidos con triazol y su uso como antagonistas de receptor purinergico p2x3 y/o p2x2/3.
HK1160136A1 (zh) 苯基吡咯氨基胍衍生物
TW200613302A (en) Nk1 antagonists
WO2004099197A3 (fr) Oxyarenes substitues
WO2006066173A3 (fr) Nouveaux antagonistes de recepteur mch
WO2006044293A3 (fr) Composes bicycliques utilises comme antagonistes du recepteur d'hormone concentrant la melanine selectifs destines au traitement de l'obesite et de troubles associes
WO2006067428A3 (fr) Agents therapeutiques
MXPA05013151A (es) 3-fluoro-piperidinas como antagonistas de n-metil-d-aspartato/nr2b.
TW200503619A (en) Use of isoindolinone derivatives as insecticides
WO2007012670A3 (fr) Composes derives de 5-benzylidene imidazolidine 2,4-dione et leur utilisation en tant qu'antagonistes de mchr-1
MX2007007152A (es) Antagonista de naurocinina-1 con anillo en puente.
MX2007000240A (es) Derivados de [1.2]-oxazin-3,5-diona y dihidropirona sustituidos con fenilo.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06806731

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载